Nextleaf Solutions Reports Fiscal Q2 2026 Results
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) ("Nextleaf" or the "Company") a multi-patented Canadian cannabis processor, announced financial results for Q2 FY2026 (ended March 31, 2026), with gross revenue of $3,338,310 and gross profit of $914,536 (38% gross margin). The quarter reflects deliberate investment in commercial infrastructure, including a national sales agency, qualified export ready platform, and a second
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2026-06-01 9:30 AM EDT | Nextleaf Solutions Ltd.
CBIH Completes Cannabinoid-Based Melanoma Patent Application Program Focused on Cannabinoid Science and Epigenetic Regulation
Houston, Texas--(Newsfile Corp. - June 1, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company focused on cannabinoid biotechnology, applied research, and therapeutic innovation, today announced the completion of a patent-ready melanoma research program focused on cannabinoid science, oncology biology, aging-related cellular stress, and epigenetic regulation. The Company views this milestone as part of its broader strategy to build research-driven int
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-06-01 7:00 AM EDT | Cannabis Bioscience International Holdings
Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of Directors
Montreal, Quebec--(Newsfile Corp. - June 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the appointment of Dr. John Lambert to its Board of Directors, effective immediately. Dr. Lambert brings more than four decades of scientific leadership and pioneering expertise in the development of antibody-drug conjugates ("ADCs"), f
Biotechnology, Pharmaceuticals, Health
2026-06-01 3:15 AM EDT | Defence Therapeutics Inc.
Theralase(R) Releases Q1 2026 Financial Statements
Toronto, Ontario--(Newsfile Corp. - May 29, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancer, bacteria and viruses has released the Company's unaudited interim consolidated financial statements for the three-month period ended March
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-05-29 5:04 PM EDT | Theralase Technologies Inc.
Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis Meterissian
Montreal, Quebec--(Newsfile Corp. - May 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, announces that Dr. Sarkis Meterissian resigned today from the Board of Directors of Defence to deepen engagement with the Company by joining the Scientific Advisory Board ("SAB"). Defence Therapeutics' current SAB is composed of Rob Leanna, PhD,
Biotechnology, Pharmaceuticals, Health
2026-05-29 4:30 PM EDT | Defence Therapeutics Inc.
Merci Dupre Clothiers Highlights Growing Concerns Around Environmental Pollutants with Innovative Enviremware Technology
Franklin, Tennessee--(Newsfile Corp. - May 29, 2026) - Recent national conversations about toxic chemicals in everyday products are reshaping how consumers evaluate what they wear, with growing scrutiny of substances such as BPA, PFAS "forever chemicals" and other compounds commonly found in textiles and performance fabrics. As awareness surrounding fabric safety and environmental exposure increases, Merci Dupre Clothiers is posit
Biotechnology, Food / Beverages, Health
2026-05-29 2:45 PM EDT | DRC Ventures
OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World
New York and Rockville, Maryland--(Newsfile Corp. - May 29, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "th
2026-05-29 7:20 AM EDT | OS Therapies
MustGrow Announces First Quarter 2026 Financial Results
Investor Webcast: Friday, May 29th at 4:00pm ET / 1:00pm PT Register/View Here: https://us02web.zoom.us/webinar/register/7717781882447/WN_m6cQAgeQSD6hjP6JeVpfbw Please join/register at least 5 minutes prior to the call. Email questions before 2:00pm ET to info@mustgrow.ca, which will be addressed during the Q&A portion of the webcast.
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2026-05-28 5:00 PM EDT | MustGrow Biologics Corp.
PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines
Toronto, Ontario--(Newsfile Corp. - May 27, 2026) - PharmaTher Holdin
Biotechnology, Pharmaceuticals
2026-05-27 8:00 AM EDT | PharmaTher Holdings Ltd.
OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences
New York and Rockville, Maryland--(Newsfile Corp. - May 26, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies"
2026-05-26 7:40 AM EDT | OS Therapies
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - May 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-05-26 7:00 AM EDT | Phio Pharmaceuticals Corp.
Optimi Health Advances Highest-Purity Natural Psilocybin Extract to Date
Vancouver, British Columbia--(Newsfile Corp. - May 26, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of a production run of naturally derived psilocybin extract measuring approximately 6% psilocybin content, representing the highest-purity botanical ps
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-05-26 7:00 AM EDT | Optimi Health Corp.
Entheon Announces Termination of Business Combination Agreement with Nutravisor
Toronto, Ontario--(Newsfile Corp. - May 25, 2026) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces that further to its news release dated January 19, 2026, the definitive business combination agreement dated January 19, 2026, as amended on March 9, 2026 (the "Business Combination Agreement") between the Company and Nutravisor Inc. ("Nutravisor"), pursuant to which the parties had agreed to complete a business c
Biotechnology, Cannabis, Psychedelics, Cannabis Ancillary Service Provider
2026-05-25 7:21 PM EDT | Entheon Biomedical Corp.
MustGrow Announces Non-Brokered LIFE Offering of Approximately $2 Million
Saskatoon, Saskatchewan--(Newsfile Corp. - May 25, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") is pleased to announce a non-brokered private placement of units (each, a "Unit") at a price of $0.50 per Unit for aggregate gross proceeds to the Company of approximately $2,000,000 (the "LIFE Offering"). The Company reserves the right to increase the size of the Offering, as further described in the offering docu
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2026-05-25 6:00 PM EDT | MustGrow Biologics Corp.
MustGrow Receives Texas, Utah, and Montana Registrations for TerraSante(TM) Biofertility Product
MustGrow has received approval from the agriculture departments of Texas, Utah, and Montana to commence sales of organic biofertility product TerraSanteTM. Based on infield grower data, the mustard-derived TerraSanteTM biofertility product has been shown to improve crop yields, soil, and potentially the soil microbiome health for nutrient/water use efficiencies.
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2026-05-25 7:00 AM EDT | MustGrow Biologics Corp.
TempraMed Featured on Dr. Phil Show in National US Broadcast Highlighting the Risk of Temperature Exposure for Insulin and Other Medications
Vancouver, British Columbia--(Newsfile Corp. - May 22, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed a medical technology innovator transforming how temperature sensitive medications are stored and managed, is pleased to announce that TempraMed is featured on the Dr. Phil Show in a national broadcast episode focused o
Technology, Biotechnology, Pharmaceuticals, Health
2026-05-22 11:57 AM EDT | TempraMed Technologies Ltd.
Optimi Health Announces Closing of Oversubscribed US$15 Million Public Offering
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today closed its previously announced underwritten public offering (the "Offering") in connection with the uplisting of its common shares to the Nasdaq Capital Market. The Company issued 2,400,000 common s
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-05-21 1:07 PM EDT | Optimi Health Corp.
TMC Group Commissions New Capacity to Support Next-Generation Radiotheranostics
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - As demand for radiotheranostics continues to grow exponentially, TMC Group, a Canadian manufacturer of high-purity enriched stable isotopes, is commissioning new production lines this year. This will add 50 percent more capacity to help ensure reliable supply for radiopharmaceutical research, clinical development, and future commercialization. TMC Group will be exhibiting at the 2026 Society of Nuclear Medicine and Molecular
Technology, Biotechnology, Chemical, Pharmaceuticals
2026-05-21 10:00 AM EDT | TMC Group
Britannia Life Sciences Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - May 21, 2026) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") today provides a corporate update on its current asset position, strategic direction, and capital markets initiatives. The Board of Directors has approved a refined corporate strategy which repositions Britannia as a public market "venture builder and company accelerator." Separately, the Board has also approved the commencement of a normal course issuer bid (the "NCIB")
Biotechnology, Household / Consumer / Cosmetics, Health, Cannabis Ancillary Service Provider
2026-05-21 9:08 AM EDT | Britannia Life Sciences Inc
Restart Life Sciences Closes Dedicated Purchase Order Financing Private Placement; CEO Subscribes for 50% of Offering
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that it has successfully closed its previously announced non-brokered private placement offering (the "Offering") of units (the "Units") to establish a revolving purchase order ("PO") financing source for its wholly owned subsidiary, Holy Crap Foods Inc. ("Holy Crap"). The Company has issued a total
Technology, Biotechnology, Health
2026-05-21 6:00 AM EDT | Restart Life Sciences Corp.